DT 2219ARL

Drug Profile

DT 2219ARL

Alternative Names: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219ARL; DT2219; IND100780; OXS 1550

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Class ADP ribose transferases; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II B cell lymphoma; Leukaemia

Most Recent Events

  • 19 Jul 2018 University of Minnesota entered into a material transfer agreement with an undisclosed company
  • 11 Jun 2018 Interim efficacy and adverse events data from a phase I/II trial in B-cell lymphoma and leukaemia released by GT Biopharma
  • 18 Apr 2017 Phase-II clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT02370160)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top